Trial Profile
A phase 2, 16 week, multicenter, randomized, double blind placebo controlled, parallel group proof of concept study evaluating the efficacy and safety of PF-04383119 [tanezumab] for the treatment of pain associated with interstitial cystitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Tanezumab (Primary)
- Indications Pelvic pain
- Focus Therapeutic Use
- Sponsors Pfizer
- 19 May 2015 Pooled analysis (1035, 1010, 1019) results presented at the 110th Annual Meeting of the American Urological Association.
- 17 Mar 2011 Primary endpoint 'Numerical Rating Scale' has been met according to results published in the Journal of Urology.
- 17 Mar 2011 Results published in the Journal of Urology.